A Deep Look Into the Future of Quantitative Imaging in Oncology:A Statement of Working Principles and Proposal for Change by Morin, Olivier et al.
 
 
 
A Deep Look Into the Future of Quantitative Imaging in
Oncology
Citation for published version (APA):
Morin, O., Vallieres, M., Jochems, A., Woodruff, H. C., Valdes, G., Braunstein, S. E., Wildberger, J. E.,
Villanueva-Meyer, J. E., Kearney, V., Yom, S. S., Solberg, T. D., & Lambin, P. (2018). A Deep Look Into
the Future of Quantitative Imaging in Oncology: A Statement of Working Principles and Proposal for
Change. International Journal of Radiation Oncology Biology Physics, 102(4), 1074-1082.
https://doi.org/10.1016/j.ijrobp.2018.08.032
Document status and date:
Published: 15/11/2018
DOI:
10.1016/j.ijrobp.2018.08.032
Document Version:
Publisher's PDF, also known as Version of record
Document license:
Taverne
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 09 Jan. 2021
International Journal of
Radiation Oncology
biology physics
www.redjournal.orgCritical ReviewA Deep Look Into the Future of Quantitative
Imaging in Oncology: A Statement of Working
Principles and Proposal for Change
Olivier Morin, PhD,* Martin Vallières, PhD,y Arthur Jochems, PhD,z
Henry C. Woodruff, PhD,z Gilmer Valdes, PhD,*
Steve E. Braunstein, MD, PhD,* Joachim E. Wildberger, MD,x
Javier E. Villanueva-Meyer, MD,k Vasant Kearney, PhD,*
Sue S. Yom, MD,* Timothy D. Solberg, PhD,* and Philippe Lambin, MDz
*Department of Radiation Oncology, University of California San Francisco, San Francisco,
California; yMedical Physics Unit, McGill University, Montreal, Canada; zThe D-Lab, Grow Research
Institute for Oncology, Maastricht University, Maastricht, The Netherlands; xDepartment of
Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands;
kDepartment of Radiology, University of California San Francisco, San Francisco, CaliforniaReceived Apr 27, 2018, and in revised form Aug 21, 2018. Accepted for publication Aug 21, 2018.The adoption of enterprise digital imaging, along with the development of quantitative imaging methods and the re-
emergence of statistical learning, has opened the opportunity for more personalized cancer treatments through transfor-
mative data science research. In the last 5 years, accumulating evidence has indicated that noninvasive advanced imag-
ing analytics (i.e., radiomics) can reveal key components of tumor phenotype for multiple lesions at multiple time points
over the course of treatment. Many groups using homegrown software have extracted engineered and deep quantitative
features on 3-dimensional medical images for better spatial and longitudinal understanding of tumor biology and for the
prediction of diverse outcomes. These developments could augment patient stratification and prognostication, buttres-
sing emerging targeted therapeutic approaches. Unfortunately, the rapid growth in popularity of this immature scientific
discipline has resulted in many early publications that miss key information or use underpowered patient data sets,
without production of generalizable results. Quantitative imaging research is complex, and key principles should be fol-
lowed to realize its full potential. The fields of quantitative imaging and radiomics in particular require a renewed focus
on optimal study design and reporting practices, standardization, interpretability, data sharing, and clinical trials. Stan-
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Volume 102  Number 4  2018 Quantitative imaging in oncology 1075field to move forward. A new data-sharing paradigm enacted among open and diverse participants (medical institutions,
vendors and associations) should be embraced for faster development and comprehensive clinical validation of imaging
biomarkers. In this review and critique of the field, we propose working principles and fundamental changes to the cur-
rent scientific approach, with the goal of high-impact research and development of actionable prediction models that will
yield more meaningful applications of precision cancer medicine.  2018 Published by Elsevier Inc.The Birth of a New Scientific Discipline
The role of medical imaging in oncology has expanded
considerably since the introduction of computed
tomography in the 1970s. The addition of magnetic
resonance imaging and of positron emission tomography
shortly thereafter brought forth a new level of soft-tissue
representation and improved understanding of molecular
physiology. In subsequent years, interdisciplinary teams
of radiologists, oncologists, and radiation oncologists
developed a common radiographic language to document
and communicate diagnosis and response to therapy. For
the most part, these imaging examinations wereClinical
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3-dimensional tumor heterogeneity and changes that occur oversummarized in nonstructured qualitative or semi-
quantitative reports focused on the affected organs and
the tumor environment. Recently, however, the transition
to enterprise digital imaging and re-emergence of sta-
tistical learning algorithms (i.e., machine learning) have
led to the development of many quantitative imaging
models aimed at assisting and augmenting physician
decision-making.
The term “radiomics” was introduced in 2012 as the
scientific discipline of advanced imaging analysis in med-
icine. The fundamental hypothesis of radiomics is that
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diction models and better risk stratification of patients from
and overall survival have all been studied as possible out-
the point of diagnosis may be more useful and actionable
s models refer to quantification of changes after therapy or
being proposed by the field of quantitative imaging and
e biomarkers. The current model relies on limited sampling
Radiomics may offer advantages in capturing important
time.
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plications have recently emerged, ranging from tumor
classification and phenotyping (4-7) to modeling of
locoregional control (8) and prognostication of future out-
comes (9). Specific quantitative imaging modeling studies
were performed on a comprehensive list of tumor sites,
including head and neck, (4, 8-13) lung, (3, 4, 14-18) breast,
(19-29) liver, (30, 31) cervix, (32-36) prostate, (37, 38)
extremities (sarcoma), (39, 40) and brain. (7, 41-54)
Figure 1 illustrates the many opportunities offered by
radiomics prediction models for improved risk stratification
of patients from a point-of-care perspective. Outcome
prediction models using clinical and imaging variables
could be created to calibrate or adjust treatment strategies
using combinations of surgery, radiation therapy, and sys-
temic/targeted drug delivery. Response to therapies,
including novel pharmaceutical agents, could be adaptively
modeled using radiomics analyses of serial imaging over
the treatment course (i.e., delta-radiomics or 4-dimensional
radiomics). In recent years, machine learning approaches,
including deep learning, have been proposed to augment or
replace current engineered radiomic features (43). These
approaches could usher in new treatment paradigms
(Fig. 1), in which quantitative imaging using radiomics
methods allows for a more comprehensive understanding of
tumor phenotype spatially and temporally.
In the last 5 years, an exponential increase in the number
of radiomics publications has occurred, with a widening
number of applications in many subdisciplines of radiology
and radiation oncology (55, 56). The rapid development of
the field has resulted in many publications containing re-
sults that are difficult, if not impossible, to reproduce,
which has greatly hindered the clinical translation of
actionable models. This shortcoming is based on a lack of
standardization and, therefore, variable quality of the input
data. On a basic level, many studies provide insufficient
methodologic detail and are conducted on patient cohorts
that are underpowered for statistical significance and cre-
ation of valid generalizable models. Today, there exist
many sources of variability in conducting quantitative im-
aging research (57-59). Notably, given the heterogeneity in
acquisition and reconstruction of positron emission to-
mography images, caution has been urged in developing
quantitative imaging models using positron emission to-
mography (60-63). The primary aim of quantitative imag-
ing models should be to discriminate signal amid numerous
sources of noise present in the process, and underpowered
studies will fail to produce reliable or robust results.
Similarly, the field of genomics, in its infancy, also suffered
from analyses that were nongeneralizable. At this writing,
the field of quantitative imaging and radiomics in particular
requires a renewed focus on optimal study design practices,
standardization, meaningfulness, usefulness, data sharing,
and clinical trials (56). In the coming years, international
cooperative efforts will be required to quantify the added
value of the most promising quantitative models compared
with existing methods. Furthermore, only through carefullydesigned and well-powered clinical trials will quantitative
imaging demonstrate its worth.Ensuring Quality Research
The development and clinical validation of radiomics
models face many challenges in practical implementation,
the foremost of which is that most current radiomics studies
suffer from severe reproducibility issues. Because the
workflow of radiomics prediction model development,
image acquisition and reconstruction, image post-processing
(including data compression), feature calculation, statistical
analysis, and clinical validation (Fig. 2) is highly complex,
standardization and best practice guidelines must be
implemented at every step in the workflow. Feature calcu-
lation alone involves many critical processing steps,
including, for example, image filtering, spatial interpolation,
and intensity discretization. To address the common prob-
lem of missing information about specific procedural steps
in current radiomics papers, researchers in the field recently
formed the Image Biomarker Standardization Initiative
(IBSI) (64). This international consortium champions 3
major goals: (1) to reach consensus and provide benchmark
values for the calculation of the most commonly used
radiomics features; (2) to reach consensus and provide
benchmarked values for the image processing steps required
before radiomics feature extraction; and (3) to provide a set
of guidelines for reporting comprehensive information on
radiomics experiments. Benchmark radiomics calculations
have been performed on synthetic and actual sets of clinical
images. Figure 2 provides an overview of the components of
development and clinical implementation of radiomics
models and highlights the need for comprehensive stan-
dardization of image acquisition and statistical analysis, (65,
66) similar to ongoing efforts with the IBSI.
The Transparent Reporting of a Multivariable Prediction
Model for Individual Prognosis or Diagnosis (TRIPOD)
Statement is a guideline specifically designed for the
reporting of studies developing or validating a multivariable
prediction model (65). Some of the reporting guidelines
developed by the IBSI effort will likely overlap with
TRIPOD because the method to develop diagnostic and
prognostic models in quantitative imaging should not
fundamentally differ from those in clinical medicine and
because TRIPOD should become a useful reference.
Overall, the standardization of radiomics methods in the
community is an essential requirement for faster clinical
translation, and the workflow and benchmarked values
defined by the IBSI (and TRIPOD) represent a step toward
the calibration of future radiomics investigations. Efforts of
groups in radiation oncology should evolve in concert with
the Quantitative Imaging Network (67), which is tasked
with providing recommendations for multisite clinical tri-
als. At this writing, the Quantitative Imaging Network is
evaluating a range of multimodal imaging approaches;
harmonization of image data collection; and analysis,
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Fig. 2. Comprehensive list of steps and requirements for the development and clinical validation of new radiomics models
and future clinical trials. Ongoing efforts at standardization are paramount in the following areas: (1) medical imaging
acquisition and reconstruction; (2) workflow of computation of radiomics features proposed by the Image Biomarker
Standardization Initiative (19); and (3) statistical analysis.
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platforms in order to test their performance across different
cancer sites.
After feature extraction, statistical analysis and machine
learning (Fig. 2) are needed to associate features with
tumor aggressiveness and clinical outcomes. For construc-
tion of tumor outcome prediction models via multivariable
analysis, radiomics studies valuable enough to be put on the
path toward clinical translation must (1) include testing of
radiomics-based models on independent and external
testing sets of sufficiently large size to demonstrate efficacy
or complementarity over conventional prognostic clinical
metrics and (2) ensure that all imaging data, clinical in-
formation, and programming code related to a radiomics
study are available online. Lambin et al (56) and Vallières
et al (68) have provided additional details on the quality of
radiomics studies, notably for standardization of imaging
protocols and quality assurance. High-quality and trans-
parent radiomics research is key for the growth of the field;
researchers should strive to follow the “FAIR guiding
principles” (69) by making all radiomics research objects
findable, accessible, interoperable, and reusable, thus
enabling independent validation and quality assurance of
such research efforts.Meaningfulness: Toward Interpretable
Radiomics Models
The interpretation of selected features lies at the core of any
workflow involving medical imaging. Radiographicimaging featuresdqualitative descriptors (e.g., edema, ne-
crosis, lesion/tumor contrast enhancement) noted through
visual assessment by an expert radiologistdoften have an
intuitive interpretation. Quantitative formula-derived
radiomics features, on the other hand, largely lack an
easy description and are not readily and innately connected
to an underlying biology or to the clinic. Successful clinical
integration of quantitative imaging research and machine
learning will require an increased focus on interpretable
models. Figure 3 illustrates the gap between radiographic
and radiomics models. The black-box aspect of the current
radiomics paradigm increases the reluctance of clinicians to
accept into clinical practice therapeutic decision-making
paradigms based only on opaque quantitative features.
Radiomics models should strive for more direct interpre-
tation related to better-established radiology models of
what drives a specific outcome. Deep learning approaches
are expected to face similar challenges in adoption because
of the large number of noninterpretable features. Address-
ing this issue is a topic of current investigations, and recent
research has shown that a combination of radiographic
(also called semantic) and radiomics features could in-
crease the performance of tumor classification models,
indicating an additive effect between the analyses (41).
Nonetheless, given the common source for both feature
types, it can be assumed that some overlap does exist-
dhence the need for contributions from both methods to
best capture the tumor phenotype. Identifying associations
between radiographic and radiomics features may help
clarify their relationship and provide stronger links to the
underlying biology. For example, Yip et al (55) found that
RADIOGRAPHIC RADIOMICS
Bridging 
the Gap
To understand
the predictive
value
Statistics
Texture
Shape
Deep features
Filters
Enhancement
Diffusion (ADC)
Edema
Margin
T2 level
Heterogeneity
Fig. 3. Future radiomics work will need to reduce the gap in the interpretability of radiographic and radiomics quantitative
imaging models. Radiographic features have so far shown predictive and better interpretability than pure radiomics or deep
feature models. Understandability of predictive radiomics features is the key in moving the field forward.
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at least 4 of 57 radiomics features.
Ultimately, meaningfulness stems from the core hy-
pothesis that radiomics features afford added relevant data
reflective of tumor pathophysiology that cannot be derived
from standard radiologic interpretation alone. Features
derived from radiomics analysis provide information that is
correlated to genomic, cellular, and metabolic features of
tumors, such as human papilloma virus status (70), iso-
citrate dehydrogenase mutation, estimated glomerular
filtration rate (EGFR) mutations, hypoxia, necrosis, or T
cell infiltration. Typically, some of these variables are
continuous rather than dichotomous; therefore, a scaled
descriptor, such as degree of hypoxia assessed from a
radiomics signature, may be a more suitable than a simple
binary endpoint. The 3 main advantages of a radiomics-
based approach are the cost (cheaper than genome
sequencing), its basis in information from the whole tumor
(rather than a limited biopsy, which may not capture the
heterogeneity present within the tumor), and the added
spatial resolution (e.g., one could define the level of T cell
infiltration in the primary lesion, lymph nodes and metas-
tases). It is expected that future research will continue to
bridge the gap between radiographic and radiomics features
in creating more interpretable models.Usefulness: Toward Actionable Radiomics
Signatures
The clinical utility of radiomics signatures is dependent on
several factors. Ultimately, useful quantitative imaging
research needs to add to existing knowledge or simplify
existing methods. The first step is for the radiomics models
to be generalizable. External validation of the radiomics
model is crucial to evaluate performance beyond the walls
of the institutes in which the signature was trained.
Although small, single-institution studies have value as a
conceptual demonstration of methodology and in gener-
ating new hypotheses, their lack of external validationgreatly hinders broader applicability and acceptance of
radiomics signatures in the clinic. Second, careful consid-
eration must be given to the outcome that the models are
attempting to predict. Radiomics signatures can be trained
to predict many kinds of structured, quantifiable outcomes,
but the obtained models must be actionable. Examples of
prediction types are diagnostics, prognosis, treatment
stratification and automated reporting (Fig. 1). The degree
to which a radiomics model improves current treatment
decisions is an important factor for determining usefulness.
Third, the volume and specificity of the data on which the
radiomics signature is traineddand subsequently vali-
dateddis essential. Access to large databases of medical
images is rare, largely because of the logistical hurdles
associated with data sharing in the medical field; therefore,
radiomics signatures are often derived from small cohorts
of patients. This shortcoming is a particular concern for
exploration of deep learning methods, which often require
significantly more systematically acquired patient images.
Finally, the ultimate usefulness of radiomics models will
come from studies that demonstrate that quantification of
imaging features at the organ level can safely replace
existing biomarkers and methods at the microscopic level.
Bottom-up and top-down study methods (Fig. 4) will likely
be the focus of quantitative imaging research efforts for
years to come. Combined efforts in radiomics and geno-
mics should increase the robustness of predictive models
and further resolve meaningfulness while improving
interpretability.
Once the efficacy of a given radiomics-based model has
been assessed on a sufficient number of independent and
external data sets from different institutions, the most
important step as part of clinical translation is to test its
potential benefit in influencing clinical decision-making by
improving patient outcomes in randomized clinical trials.
The clinical deployment of radiomics should be subject to
the same rigor in development and implementation as exists
with conventional novel diagnostic and therapeutic in-
terventions, with the goal of doing no harm and establishing
a clinically cost-effective and meaningful instrument. In the
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Fig. 4. Biological meaningfulness of radiomics models
will require deep understanding of DNA and proteins.
Radiomic and genomic efforts in the coming years will
likely combine via top-down and bottom-up scientific ap-
proaches. Figure modified from Parmar et al (11).
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lytics and data science must play a major role in the
development of clinical trials to better consolidate the
relevance of radiomics into routine clinical practice.Toward Deep Learning
Conventional radiomics techniques have relied mainly on
quantifying images using a finite set of human-crafted
informative features (e.g., tumor morphology, tumor in-
tensity, texture or spatial frequency information). In the
general computer vision and object recognition fields, the
use of texture features to quantify images can be traced
back to as early as 1955 (71). Machine learning algorithms,
such as random forests and gradient boosting, correlate
informative features to different outcomes. Although many
radiomics papers have been published using these tech-
niques, both random forests and gradient boosting depend
on the quality of the features provided. Using handcrafted
or explicitly designed textures may limit prediction accu-
racy on image classification tasks.
Parallel to the development of the field of radiomics in
radiation oncology, general computer vision has experi-
enced a new revolution. Motivated by the early work of
Yann LeCun et al, convolutional neural networks (CNNs)
(72) have been developed that not only correlate features to
outcomes but also design completely new sets of features.
The ability of CNNs to combine high-order featurecharacteristics (e.g., lines and circles) into new features to
distinguish images has achieved breakthrough prediction
accuracy in a variety of challenges, including the ImageNet
Large Scale Visual Recognition Competition. Publically
available high-level programming packages (e.g., Tensor-
Flow, Theano, Caffe, and PyTorch) have eliminated much
of the low-level computational rigor and helped to accel-
erate the use of deep learning algorithms applied to
radiomics tasks. Applications of CNNs in radiomics ap-
plications (deep radiomics) are starting to make headway
(44, 73). However, CNNs require more data than previous
approaches, necessitating the incorporation of transfer
learning, data augmentation, and multitask learning tech-
niques to mitigate the amount of data required. In addition,
prediction models based on deep learning can easily be
subject to biases and tend to be difficult to interpret. Efforts
should be made to understand the relationship among data
set sizes, possible confounders, and performance of
outcome prediction. Performing explicit prediction of spe-
cific biological observations (e.g., tumor necrosis, hypoxia)
may be a more realistic short-term goal than trying to ac-
count for overall survival. It is anticipated that multitask
learning will help to provide a degree of interpretation for
deep learning approaches (74). Given enough high-quality
data (text and images), it is expected that the role of
CNNs will continue to expand in medicine and quantitative
imaging (75-80).New Paradigm for Data Sharing
Rapid-learning health care is a digital framework (Fig. 5)
meant to drive scientific discovery and clinical imple-
mentation of decision-support systems at a faster pace. This
objective depends on new paradigms of easier collabora-
tion, with the aim of accumulating large, high-quality, well-
curated data sets for appropriate analysis. In oncology, this
paradigm essentially consists of unlocking and repurposing
available clinical data to accelerate knowledge acquisition
and form models that can predict cancer treatment out-
comes, with the hypothesis that past outcome results can
constantly and iteratively improve the prediction of future
outcomes (81).
In this framework, external knowledge coming from
clinical trials is used to optimize learning. Figure 5 sum-
marizes key data elements that may improve the design of
quantitative imaging-based data warehouse and clinical
trials. Contributions from multiple cancer centers will be
necessary to obtain sufficient statistical evidence that a
given image-based prediction model can improve decision-
making in the clinic for patient cohorts spanning a sub-
stantial spectrum of the population. Next, standardization
and quality assurance of image-based methods imple-
mented in any investigational project or clinical trial are
fundamental for the long-term reproducibility of applica-
tion of a given model. In addition, the use of dedicated
image-based ontologies, such as the Radiomics Ontology
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Fig. 5. Keys to the successful implementation of quantitative imaging data warehouse for new research and clinical trials in
oncology. Orchestrated participation by multiple institutions, national boards, manufacturers, and scientific associations is
necessary to achieve the best approach for unlocking trapped oncology data for quantitative data warehouses. Successful
institutions will implement clinical and informatic infrastructure changes to accumulate data from electronic health records,
Oncology Information System, patient outcomes, picture archives and communication systems, and other research auxiliary
databases. Adoption of standardization, quality assurance, ontologies, and distributed learning methods will ensure optimal
worldwide rapid health care learning.
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facilitate the interoperability of analyses via standardized
reporting and descriptions of radiomics methods. Finally,
the participation of all health care actors, including gov-
ernment entities (e.g., the National Cancer Institute and the
National Institutes of Health), professional associations
(e.g., the Radiological Society of North America, the
American Society for Radiation Oncology, and the Amer-
ican Association of Physicists in Medicine), patient advo-
cacy groups, and industry would significantly improve the
technical and practical aspects of data sharing and clinical
trial designs. Such a vision will require better integration of
electronic health record with oncology information systems
and picture archiving and communication systems
(PACS). Standardized communication formats (e.g., Fast
Healthcare Interoperability Resources [https://www.hl7.
org/fhir/overview.html]) may become the leading vehicle
to share medical data and instructions between existing
systems.
Increasing evidence demonstrates that high-dimensional
quantitative information extracted from medical images of
cancer constitutes an invaluable source of data that could be
used to better decode tumor biology and support clinical
decision-making. Fortunately, anatomic and physiological
imaging is now acquired routinely at every step of clinical
cancer management, from tumor diagnosis to tumor stag-
ing, treatment planning, treatment delivery (e.g., cone beam
computed tomography) (82), treatment response moni-
toring and long-term follow-up. Moreover, the ability tometiculously select, mine and combine different medical
imaging components into actionable clinical models via
advanced quantitative image analysis and machine learning
has reached an unprecedented level. To fully harness the
potential benefits of these immense sources of data and
state-of-the-art techniques, but most of all for a faster
translation of quantitative imaging-based decision support
into the clinical environment, it is crucial that all members
of the medical imaging community act together to create
worldwide consortiums, with the aim to improve practices,
standardization, meaningfulness, usefulness, data sharing
and clinical trial designs. A tangible first step could be to
fully incorporate simple metrics, such as tumor size and
shape in the temporal management of cancer, whenever
adequate. It will only be then that we will begin to realize
the full potential of medical imaging and observe more
rapid translation of quantitative imaging-based models into
routine clinical practice.
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